163 related articles for article (PubMed ID: 16023200)
1. Therapeutic potential of nanoparticulate systems for macrophage targeting.
Chellat F; Merhi Y; Moreau A; Yahia L
Biomaterials; 2005 Dec; 26(35):7260-75. PubMed ID: 16023200
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy.
Kunjachan S; Jose S; Thomas CA; Joseph E; Kiessling F; Lammers T
Fundam Clin Pharmacol; 2012 Feb; 26(1):63-71. PubMed ID: 21631585
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticulate delivery systems for antiviral drugs.
Lembo D; Cavalli R
Antivir Chem Chemother; 2010; 21(2):53-70. PubMed ID: 21107015
[TBL] [Abstract][Full Text] [Related]
5. Engineered nanoparticles as precise drug delivery systems.
Yih TC; Al-Fandi M
J Cell Biochem; 2006 Apr; 97(6):1184-90. PubMed ID: 16440317
[TBL] [Abstract][Full Text] [Related]
6. The influence of pulmonary surfactant on nanoparticulate drug delivery systems.
Schleh C; Rothen-Rutishauser B; Kreyling WG
Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis.
Choudhury RP; Lee JM; Greaves DR
Nat Clin Pract Cardiovasc Med; 2005 Jun; 2(6):309-15. PubMed ID: 16265535
[TBL] [Abstract][Full Text] [Related]
8. The monocyte/macrophage as a therapeutic target in atherosclerosis.
Saha P; Modarai B; Humphries J; Mattock K; Waltham M; Burnand KG; Smith A
Curr Opin Pharmacol; 2009 Apr; 9(2):109-18. PubMed ID: 19230773
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases.
Singh A; Talekar M; Raikar A; Amiji M
J Control Release; 2014 Sep; 190():515-30. PubMed ID: 24747762
[TBL] [Abstract][Full Text] [Related]
10. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages.
van Rooijen N
J Drug Target; 2008 Aug; 16(7):529-34. PubMed ID: 18686122
[TBL] [Abstract][Full Text] [Related]
11. Macrophage inflammatory response to self-assembling rosette nanotubes.
Journeay WS; Suri SS; Moralez JG; Fenniri H; Singh B
Small; 2009 Jun; 5(12):1446-52. PubMed ID: 19242939
[TBL] [Abstract][Full Text] [Related]
12. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery.
Chandrasekar D; Sistla R; Ahmad FJ; Khar RK; Diwan PV
J Biomed Mater Res A; 2007 Jul; 82(1):92-103. PubMed ID: 17269145
[TBL] [Abstract][Full Text] [Related]
13. Targeting of nanoparticles to the clathrin-mediated endocytic pathway.
Harush-Frenkel O; Debotton N; Benita S; Altschuler Y
Biochem Biophys Res Commun; 2007 Feb; 353(1):26-32. PubMed ID: 17184736
[TBL] [Abstract][Full Text] [Related]
14. Targeting to carcinoma cells with chitosan- and starch-coated magnetic nanoparticles for magnetic hyperthermia.
Kim DH; Kim KN; Kim KM; Lee YK
J Biomed Mater Res A; 2009 Jan; 88(1):1-11. PubMed ID: 18257079
[TBL] [Abstract][Full Text] [Related]
15. [In vitro dexamethasone release from nanoparticles and its pharmacokinetics in the inner ear after administration of the drug-loaded nanoparticles via the round window].
Chen G; Hou SX; Hu P; Hu QH; Guo DD; Xiao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):1022-4. PubMed ID: 18583254
[TBL] [Abstract][Full Text] [Related]
16. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.
Deng X; Yu Z; Funayama H; Yamaguchi K; Sasano T; Sugawara S; Endo Y
Int Immunopharmacol; 2007 Feb; 7(2):152-61. PubMed ID: 17178381
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail.
Juillerat-Jeanneret L; Schmitt F
Med Res Rev; 2007 Jul; 27(4):574-90. PubMed ID: 17022028
[TBL] [Abstract][Full Text] [Related]
18. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
[TBL] [Abstract][Full Text] [Related]
19. Medical application of functionalized magnetic nanoparticles.
Ito A; Shinkai M; Honda H; Kobayashi T
J Biosci Bioeng; 2005 Jul; 100(1):1-11. PubMed ID: 16233845
[TBL] [Abstract][Full Text] [Related]
20. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
Gonzalez-Rey E; Delgado M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
